Mineralys Therapeutics Inc [NASDAQ: MLYS] stock went on an upward path that rose over 86.43% on Tuesday, amounting to a one-week price increase of more than 95.79%.
Over the last 12 months, MLYS stock rose by 134.44%. The one-year Mineralys Therapeutics Inc stock forecast points to a potential upside of 23.18. The average equity rating for MLYS stock is currently 1.29, trading closer to a bullish pattern in the stock market.
The market cap for the stock reached $1.91 billion, with 65.73 million shares outstanding and 42.81 million shares in the current float. Compared to the average trading volume of 825.45K shares, MLYS stock reached a trading volume of 15694387 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on Mineralys Therapeutics Inc [MLYS]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for MLYS shares is $37.57 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on MLYS stock is a recommendation set at 1.29. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Jefferies have made an estimate for Mineralys Therapeutics Inc shares, keeping their opinion on the stock as Hold, with their previous recommendation back on June 11, 2025. While these analysts kept the previous recommendation, H.C. Wainwright raised their target price to Buy. The new note on the price target was released on July 10, 2024, representing the official price target for Mineralys Therapeutics Inc stock. Previously, the target price had yet another raise to $30, while Goldman analysts kept a Buy rating on MLYS stock.
The Price to Book ratio for the last quarter was 6.05, with the Price to Cash per share for the same quarter was set at 4.90.
MLYS Stock Performance Analysis:
Mineralys Therapeutics Inc [MLYS] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 95.79. With this latest performance, MLYS shares gained by 111.20% in over the last four-week period, additionally plugging by 222.82% over the last 6 months – not to mention a rise of 134.44% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for MLYS stock in for the last two-week period is set at 89.11, with the RSI for the last a single of trading hit 2.35, and the three-weeks RSI is set at 1.51 for Mineralys Therapeutics Inc [MLYS]. The present Moving Average for the last 50 days of trading for this stock 14.44, while it was recorded at 17.98 for the last single week of trading, and 13.26 for the last 200 days.
Mineralys Therapeutics Inc (MLYS) Capital Structure & Debt Analysis
According to recent financial data for Mineralys Therapeutics Inc. ( MLYS), the Return on Equity (ROE) stands at -63.21%, highlighting a negative impact on investor capital. The Return on Assets (ROA) is -58.32%, reflecting the company’s efficiency in generating profits from its assets. Additionally, Mineralys Therapeutics Inc’s Return on Invested Capital (ROIC) is -60.84%, showcasing its effectiveness in deploying capital for earnings.
Mineralys Therapeutics Inc (MLYS) Efficiency & Liquidity Metrics
Based on Mineralys Therapeutics Inc’s (MLYS) latest financial statements, the Debt-to-Equity Ratio is 0.00%, indicating its reliance on debt financing relative to shareholder equity.
Mineralys Therapeutics Inc (MLYS) Efficiency & Liquidity Metrics
From an operational efficiency perspective, Mineralys Therapeutics Inc. (MLYS) effectively leverages its workforce, generating an average of -$3740588.24 per employee. The company’s liquidity position is robust, with a Current Ratio of 15.12% and a Quick Ratio of 15.12%, indicating strong ability to cover short-term liabilities.
MLYS Stock EPS
With the latest financial reports released by the company, Mineralys Therapeutics Inc posted -1.13/share EPS, while the average EPS was predicted by analysts to be reported at -0.83/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -0.3. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for MLYS. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Mineralys Therapeutics Inc go to 6.59%.
Mineralys Therapeutics Inc [MLYS] Institutonal Ownership Details
There are presently around $112.88%, or 114.32%% of MLYS stock, in the hands of institutional investors. The top three institutional holders of MLYS stocks are: CATALYS PACIFIC, LLC with ownership of 9.19 million shares, which is approximately 18.629%. SAMSARA BIOCAPITAL, LLC, holding 5.07 million shares of the stock with an approximate value of $$59.38 million in MLYS stocks shares; and SAMSARA BIOCAPITAL, LLC, currently with $$56.76 million in MLYS stock with ownership which is approximately 9.8285%.
